CHEMOKINES IN THE PATHOGENESIS OF ASTHMA

哮喘发病机制中的趋化因子

基本信息

  • 批准号:
    6106522
  • 负责人:
  • 金额:
    $ 13.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-11-01 至 1999-10-31
  • 项目状态:
    已结题

项目摘要

Chemokines in the Pathogenesis of Asthma. Asthma represents a serious health problem particularly for inner city children. Recent studies have identified that many of the asthmatic attacks are triggered by exposure to cockroach allergens however, the mediators within the lung that dictate progression of disease have still not been fully defined. While many potential mediators have been examined previously, asthma still exacts a toll on the patients. More specific, targeted therapy has the potential to improve the treatment of asthma by identifying those mediators directly responsible for the pathogenesis of the disease. This project will test the hypothesis that asthma-like pulmonary injury is mediated by the local production of chemokines. Chemokines are small molecular weight peptides which induce the chemotaxis and recruitment of inflammatory cells. They are powerful mediators with long lasting and potent biological activities. Our first specific aim will determine the acute and chronic pulmonary inflammation that develops after direct injection of the chemokines into the lung. The assessment of the injury will include histologic and morphometric analysis as well as an assessment of the innervation of the airways. The second specific aim will develop a mouse model of asthma-like pulmonary inflammation in response to cockroach allergens. This model will be established by locating households with high levels of cockroach allergens (done in conjunction with the other two research projects) and using this material to immunize the mice. The mice will be challenged by exposure to aerosols containing the dust with the cockroach allergens and the pulmonary injury carefully quantitated including an analysis of innervation of the airways. Our third specific aim will investigate the biochemical pathways responsible for the upregulation of the chemokines in cells sensitized and then challenged with cockroach allergens. We will focus on reactive oxygen and reactive nitrogen intermediates since they have been demonstrated to increased the transcription of chemokines. Our last specific aim will rigorously test the central hypothesis that chemokines are important in the pathogenesis of asthma. This will be tested by blocking the biological activity of the chemokines with specific neutralizing antibodies and determining if there is a reduction in the pulmonary inflammation induced by repeated exposures to the cockroach allergens. Successful completion of our project will both delineate the underlying mechanisms of disease and identify potential novel targets for intervention.
趋化因子在哮喘发病机制中的作用哮喘是一种严重的 健康问题,特别是对市中心的儿童。最近的研究表明 发现许多哮喘发作是由暴露于 然而,蟑螂变应原是肺内决定 疾病的发展仍然没有得到充分的定义。虽然很多人 潜在的介质以前已经被检查过了,哮喘仍然需要 给病人造成的损失。更具体地说,靶向治疗有可能 通过直接识别这些介质来改进哮喘的治疗 对这种疾病的发病机制负有责任。该项目将测试 哮喘样肺损伤是由局部介导的假说 趋化因子的产生。趋化因子是一种小分子多肽 诱导炎性细胞的趋化和募集。他们 是具有持久和强大生物活性的强有力的介体。 我们的第一个具体目标是确定急性和慢性肺病 将趋化因子直接注入体内后发生的炎症 肺部。对损伤的评估将包括组织学和 形态计量学分析及神经支配的评价 航空公司。第二个具体目标是开发一种类似哮喘的小鼠模型 蟑螂变应原引起的肺部炎症。这款车型将 通过定位蟑螂水平较高的家庭来建立 过敏原(与其他两个研究项目一起完成)和 用这种材料给小鼠免疫。小鼠将受到挑战, 暴露于含有蟑螂变应原粉尘的气雾剂和 仔细量化的肺损伤包括分析 呼吸道的神经支配。我们的第三个具体目标是调查 趋化因子上调的生化途径 细胞致敏,然后用蟑螂过敏原攻击。我们会 关注活性氧和活性氮中间体,因为它们 已被证明能增加趋化因子的转录。我们的 最后一个具体目标将严格检验中心假设 趋化因子在哮喘的发病机制中起重要作用。这将是 通过特异性阻断趋化因子的生物活性进行测试 中和抗体并确定是否有减少的 蟑螂反复暴露引起的肺部炎症 过敏原。我们的项目的成功完成将既勾勒出 疾病的潜在机制,并确定潜在的新靶点 干预。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel G. Remick其他文献

Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies.
脂多糖 (LPS) 刺激的人全血中双相产生 IL-8。
  • DOI:
  • 发表时间:
    1992
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    L. Deforge;J. Kenney;M. Jones;Jeffrey S. Warren;Daniel G. Remick
  • 通讯作者:
    Daniel G. Remick
The biological activity of lipopolyscaccharide binding protein is determined by concentration
  • DOI:
    10.1016/s0016-5085(00)86238-1
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Richard D. Klein;Andrew C. Schook;Alireza Schook;William H. Alarcon;Lars Steinstraesser;Hongyu Zhang;Stewart C. Wang;Daniel G. Remick;Grace L. Su
  • 通讯作者:
    Grace L. Su
Nitric oxide regulation of IL-8 expression in human endothelial cells.
一氧化氮对人内皮细胞 IL-8 表达的调节。
Tumor necrosis factor inhibitors for the treatment of asthma
  • DOI:
    10.1007/s11882-007-0013-3
  • 发表时间:
    2007-03-01
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Jiyoun Kim;Daniel G. Remick
  • 通讯作者:
    Daniel G. Remick
Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation.
气管内施用内毒素和细胞因子。
  • DOI:
    10.1006/clin.1994.1117
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Thomas R. Ulich;Eunhee S. Yi;Songmei Yin;Craig A. Smith;Daniel G. Remick
  • 通讯作者:
    Daniel G. Remick

Daniel G. Remick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel G. Remick', 18)}}的其他基金

Mechanisms of improved organ function following sepsis treatment with vitamin c, thiamine and hydrocortisone (triple therapy)
维生素 C、硫胺素和氢化可的松治疗败血症后改善器官功能的机制(三联疗法)
  • 批准号:
    9978302
  • 财政年份:
    2020
  • 资助金额:
    $ 13.05万
  • 项目类别:
Mechanisms of augmented host defenses after mild brain injury
轻度脑损伤后增强宿主防御的机制
  • 批准号:
    9246802
  • 财政年份:
    2017
  • 资助金额:
    $ 13.05万
  • 项目类别:
Mechanisms of phagocytic cell defects induced by inhibitory IgG
抑制性IgG诱导吞噬细胞缺陷的机制
  • 批准号:
    8751338
  • 财政年份:
    2014
  • 资助金额:
    $ 13.05万
  • 项目类别:
Adenosine and Oxygen Modulate Antimicrobial Defenses
腺苷和氧调节抗菌防御
  • 批准号:
    8338793
  • 财政年份:
    2011
  • 资助金额:
    $ 13.05万
  • 项目类别:
Adenosine and Oxygen Modulate Antimicrobial Defenses
腺苷和氧调节抗菌防御
  • 批准号:
    8085386
  • 财政年份:
    2011
  • 资助金额:
    $ 13.05万
  • 项目类别:
Adenosine and Oxygen Modulate Antimicrobial Defenses
腺苷和氧调节抗菌防御
  • 批准号:
    8478144
  • 财政年份:
    2011
  • 资助金额:
    $ 13.05万
  • 项目类别:
Adenosine and Oxygen Modulate Antimicrobial Defenses
腺苷和氧调节抗菌防御
  • 批准号:
    8668080
  • 财政年份:
    2011
  • 资助金额:
    $ 13.05万
  • 项目类别:
Immunobiology of Trauma
创伤免疫生物学
  • 批准号:
    8280447
  • 财政年份:
    2010
  • 资助金额:
    $ 13.05万
  • 项目类别:
Immunobiology of Trauma
创伤免疫生物学
  • 批准号:
    9217919
  • 财政年份:
    2010
  • 资助金额:
    $ 13.05万
  • 项目类别:
Immunobiology of Trauma
创伤免疫生物学
  • 批准号:
    8501538
  • 财政年份:
    2010
  • 资助金额:
    $ 13.05万
  • 项目类别:

相似国自然基金

Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
  • 批准号:
    81660467
  • 批准年份:
    2016
  • 资助金额:
    39.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Atypical Chemokine Receptors orchestrate changes in vascular patterning during fibrotic liver disease via Endothelial-to-Mesenchymal Transition.
非典型趋化因子受体通过内皮-间质转化协调纤维化肝病期间血管模式的变化。
  • 批准号:
    MR/Y013751/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Research Grant
Potential role of chemokine (C-C motif) ligand 18 in the development of obese asthma and Type 2 inflammation using epidemiological and experimental studies
使用流行病学和实验研究发现趋化因子(C-C 基序)配体 18 在肥胖哮喘和 2 型炎症发展中的潜在作用
  • 批准号:
    23K09664
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of chemokine receptor signaling
趋化因子受体信号传导的调节
  • 批准号:
    10622915
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
Structure-based inhibition of chemokine signaling in the inflamed pancreas
基于结构的炎症胰腺趋化因子信号传导抑制
  • 批准号:
    10656002
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
  • 批准号:
    478877
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Operating Grants
Mechanism of metastatic control by chemokine receptor ACKR3
趋化因子受体ACKR3控制转移的机制
  • 批准号:
    23K06639
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
PET 成像评估新型趋化因子拮抗剂保护 ADRD 突触
  • 批准号:
    10818903
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
Development of A Dual Chemokine CCL2/CCL5 Neutralizing Single-domainAntibody for Treating Non-alcoholic Steatohepatitis
双趋化因子 CCL2/CCL5 中和单域抗体的开发用于治疗非酒精性脂肪性肝炎
  • 批准号:
    10761039
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
Integrated Imaging Tools for Intercellular Chemokine Signalling
用于细胞间趋化因子信号转导的集成成像工具
  • 批准号:
    10706896
  • 财政年份:
    2023
  • 资助金额:
    $ 13.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了